{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:43:00Z","timestamp":1761648180869},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,2]],"date-time":"2014-06-02T00:00:00Z","timestamp":1401667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.ijid.2014.04.020","type":"journal-article","created":{"date-parts":[[2014,6,6]],"date-time":"2014-06-06T16:46:06Z","timestamp":1402073166000},"page":"130-135","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"25","author":[{"given":"Hai-Yin","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Na","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2014.04.020_bib0005","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jama.279.6.450","article-title":"Improved survival among HIV-infected individuals following initiation of antiretroviral therapy","volume":"279","author":"Hogg","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2014.04.020_bib0010","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1001\/archinte.163.9.1009","article-title":"The growing burden of tuberculosis: global trends and interactions with the HIV epidemic","volume":"163","author":"Corbett","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijid.2014.04.020_bib0015","unstructured":"Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach: 2010 Revision. Geneva: World Health Organization; 2010."},{"key":"10.1016\/j.ijid.2014.04.020_bib0020","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1128\/AAC.02023-12","article-title":"Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug\u2013drug interaction on efavirenz concentrations in HIV\/tuberculosis-coinfected patients","volume":"57","author":"Manosuthi","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2014.04.020_bib0025","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1742-6405-8-41","article-title":"The antiretroviral efficacy of highly active antiretroviral therapy and plasma nevirapine concentrations in HIV\u2013TB co-infected Indian patients receiving rifampicin based antituberculosis treatment","volume":"8","author":"Sinha","year":"2011","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.ijid.2014.04.020_bib0030","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1742-6405-7-8","article-title":"Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV\/TB co-infected Thai adults","volume":"7","author":"Uttayamakul","year":"2010","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.ijid.2014.04.020_bib0035","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/QAI.0b013e3181d36024","article-title":"Evaluation of the safety of nevirapine therapy during pregnancy","volume":"54","author":"Bersoff-Matcha","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijid.2014.04.020_bib0040","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1097\/00002030-199813000-00008","article-title":"Suppression of plasma viral load below 20 copies\/ml is required to achieve a long-term response to therapy","volume":"12","author":"Raboud","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2014.04.020_bib0045","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/00126334-200008150-00006","article-title":"RNA virologic outcome at 52-weeks follow-up in antiretroviral clinical trials. The INCAS and AVANTI Study Groups","volume":"24","author":"Raboud","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijid.2014.04.020_bib0050","unstructured":"World Health Organization. Treatment of tuberculosis: guidelines for national programs. 3rd ed. Geneva: WHO; 2003."},{"key":"10.1016\/j.ijid.2014.04.020_bib0055","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/sim.4780060325","article-title":"Methods for combining randomized clinical trials: strengths and limitations","volume":"6","author":"Demets","year":"1987","journal-title":"Stat Med"},{"key":"10.1016\/j.ijid.2014.04.020_bib0060","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ijid.2014.04.020_bib0065","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.ijid.2014.04.020_bib0070","doi-asserted-by":"crossref","first-page":"e1154","DOI":"10.1016\/j.ijid.2013.08.006","article-title":"Early changes in hepatic function among HIV\u2013tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy","volume":"17","author":"Padmapriyadarsini","year":"2013","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2014.04.020_bib0075","doi-asserted-by":"crossref","first-page":"e84585","DOI":"10.1371\/journal.pone.0084585","article-title":"Incidence of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome and impact on patient outcome","volume":"8","author":"Bonnet","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2014.04.020_bib0080","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/1471-2334-13-482","article-title":"Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study","volume":"13","author":"Sinha","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2014.04.020_bib0085","first-page":"360","article-title":"Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB\u2013HIV co-infection in Botswana","volume":"13","author":"Shipton","year":"2009","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijid.2014.04.020_bib0090","unstructured":"Matteelli A, Kouanda S, Saleri N, Ouedraogo G. Efficacy and safety of nevirapine- vs efavirenz based ART in TB\/HIV patients in Burkina Faso: a clinical and pharmacokinetic study. Abstract 47462. 20th Conference on Retroviruses and Opportunistic Infections; 2013."},{"key":"10.1016\/j.ijid.2014.04.020_bib0095","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1473-3099(13)70007-0","article-title":"Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial","volume":"13","author":"Bonnet","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2014.04.020_bib0100","first-page":"39","article-title":"Nonnucleoside analogue use with rifampicin in HIV-infected patients with tuberculosis","volume":"10","author":"Villar Garcia","year":"2009","journal-title":"HIV Med"},{"key":"10.1016\/j.ijid.2014.04.020_bib0105","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/cid\/cir447","article-title":"Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial","volume":"53","author":"Swaminathan","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2014.04.020_bib0110","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1468-1293.2008.00563.x","article-title":"Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin","volume":"9","author":"Manosuthi","year":"2008","journal-title":"HIV Med"},{"key":"10.1016\/j.ijid.2014.04.020_bib0115","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/jama.300.5.530","article-title":"Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy","volume":"300","author":"Boulle","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2014.04.020_bib0120","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1086\/599114","article-title":"A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study","volume":"48","author":"Manosuthi","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.ijid.2014.04.020_bib0125","first-page":"CD004246","article-title":"Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naive individuals","author":"Mbuagbaw","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijid.2014.04.020_bib0130","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1086\/599115","article-title":"Efavirenz and nevirapine interactions with rifampicin: resolving the dilemmas?","volume":"48","author":"Lalloo","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2014.04.020_bib0135","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1097\/QAD.0b013e3283550e20","article-title":"Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment","volume":"26","author":"Oudijk","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2014.04.020_bib0140","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1517\/17425250903393752","article-title":"Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all","volume":"6","author":"Kwara","year":"2010","journal-title":"Exp Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ijid.2014.04.020_bib0145","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3851\/IMP1455","article-title":"Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries","volume":"14","author":"Maartens","year":"2009","journal-title":"Antivir Ther"},{"key":"10.1016\/j.ijid.2014.04.020_bib0150","unstructured":"Bonnet M, Jani IV. Pharmacokinetics of nevirapine in tuberculosis\u2013HIV co-infected patients receiving rifampicin ANRS12146 (CARINEMO). International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, July 19-22, 2009."},{"key":"10.1016\/j.ijid.2014.04.020_bib0155","doi-asserted-by":"crossref","first-page":"e68995","DOI":"10.1371\/journal.pone.0068995","article-title":"Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis","volume":"8","author":"Pillay","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2014.04.020_bib0160","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00228-008-0481-y","article-title":"Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients","volume":"65","author":"Elsherbiny","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ijid.2014.04.020_bib0165","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0140-6736(94)90693-9","article-title":"Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. The Makerere University\u2013Case Western University Research Collaboration","volume":"344","author":"Okwera","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2014.04.020_bib0170","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1473-3099(05)70140-7","article-title":"Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals","volume":"5","author":"Lawn","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2014.04.020_bib0175","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1473-3099(11)70094-9","article-title":"Reducing mortality from HIV infection and tuberculosis","volume":"11","author":"Koole","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2014.04.020_bib0180","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1007\/s10461-011-9939-5","article-title":"A systematic review of the psychiatric side-effects of efavirenz","volume":"15","author":"Kenedi","year":"2011","journal-title":"AIDS Behav"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971214015161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971214015161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T15:27:21Z","timestamp":1538580441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971214015161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":36,"alternative-id":["S1201971214015161"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2014.04.020","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2014.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}